PD-Rx Pharmaceuticals Valuation
Is PDRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Book gegen Gleichaltrige
Price-To-Book gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of PDRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von PDRX für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von PDRX für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PDRX?
Other financial metrics that can be useful for relative valuation.
| What is PDRX's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$9.05m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does PDRX's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.7x | ||
COSM Cosmos Health | 0.3x | 98.3% | US$11.7m |
ACBM Acro Biomedical | 18.6x | n/a | US$6.3m |
BIMI BIMI Holdings | 2.5x | n/a | US$21.7m |
ATPC Agape ATP | 5.5x | n/a | US$24.1m |
PDRX PD-Rx Pharmaceuticals | n/a | n/a | US$9.0m |
Price-To-Book gegen Gleichaltrige: Price-To-Book Unzureichende Daten für die Berechnung des Verhältnisses von PDRX zu anderen Unternehmen für die Bewertungsanalyse.
Price to Earnings Ratio vs Industry
How does PDRX's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Book gegen Industrie: Unzureichende Daten zur Berechnung des Verhältnisses PDRX's Price-To-Book im Vergleich zur Branche für die Bewertungsanalyse.
Price to Book Ratio vs Fair Ratio
What is PDRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | n/a |
| Fair PB Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von PDRX für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.